Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
NCT03927144 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to compare the sustained long-term benefit between two treatment paradigms of migraine prophylactic agents (erenumab versus a control arm of oral prophylactics) in episodic migraine patients who have previously failed 1 to 2 prophylactic migraine treatments.
Conditions Studied
Interventions
- DRUG AMG334
- DRUG Oral Prophylactic
Study Locations (20)
Connecticut
- Yale Center for Clinical Research — New Haven
- New England Institute for Neurology and Headache — Stamford
Florida
- University of Miami Headache Division — Miami
- Premier Research Institute — West Palm Beach
Illinois
- Diamond Headache Clinic — Chicago
- Robbins Headache Clinic — Riverwoods
Massachusetts
- Medvadis — Watertown
- New England Regional Headache Center, Inc — Worcester
Missouri
- Study Metrix Research — City of Saint Peters
- Mercy Health Research — St Louis
Texas
- Texas Neurology — Dallas
- Texas Institute for Neurological Disorders — Sherman
California
- Stanford Headache Center — Stanford
District of Columbia
- George Washington Hospital — Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 621 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2022-09-30 |
| Phase | Phase 4 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03927144
The ClinicalTrials.gov registry entry for NCT03927144 describes a study currently listed as completed. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 621 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 266 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Episodic Migraine appearing as the primary indexed condition, and to 2 interventions — of which AMG334 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03927144 reports 20 study locations spanning 14 distinct geographic areas — top geographies include Connecticut, Florida, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03927144 about?
NCT03927144 is a clinical study titled "Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients". The purpose of this study is to compare the sustained long-term benefit between two treatment paradigms of migraine prophylactic agents (erenumab versus a control arm of oral prophylactics) in episodic migraine patients who have previously failed 1 to 2 prophylactic migraine treatments.
What is the current status of trial NCT03927144?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 621 participants. The study started on 2019-05-15. Estimated completion is 2022-09-30.
What conditions does trial NCT03927144 study?
This clinical trial studies the following conditions: Episodic Migraine. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03927144?
The interventions under investigation include: AMG334 (DRUG), Oral Prophylactic (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03927144?
This trial is sponsored by Amgen, which has 266 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03927144 being conducted?
This trial has 20 study locations across California, Connecticut, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.